ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update

(2015) Y Saito et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response

(2015) CC Wen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic considerations in the treatment of gout

(2015) Rebecca L Roberts et al.   PHARMACOGENOMICS

An open-label, 6-month study of allopurinol safety in gout: The LASSO study

(2015) Michael A. Becker et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout

(2014) Lisa K. Stamp et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage

(2013) Garry G. Graham et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

(2010) Lisa K. Stamp et al.   ARTHRITIS AND RHEUMATISM